Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Imatinib in the treatment of solid tumours Duffaud F; Le Cesne ATarget Oncol 2009[Jan]; 4 (1): 45-56The extraordinary success of imatinib in gastrointestinal stromal tumors (GIST) represents a model for molecularly targeted therapy for other solid tumors. Research is currently going to identify the molecular basis of mechanisms of action and drug resistance. In this article, we review recent advances in the clinical management of patients with GISTs treated with imatinib, but also of patients with dermatofibrosarcoma protuberans, chordoma, aggressive fibromatosis, and some other common solid tumors treated with this drug. We reviewed the knowledge of the molecular mechanisms that are basic to imatinib effects in these tumors.|Adjuvants, Immunologic/administration & dosage[MESH]|Antineoplastic Combined Chemotherapy Protocols/*therapeutic use[MESH]|Benzamides[MESH]|Chordoma/*drug therapy/pathology[MESH]|Clinical Trials as Topic[MESH]|Dermatofibrosarcoma/*drug therapy/genetics/pathology[MESH]|Desmoid Tumors/drug therapy/pathology[MESH]|Fusion Proteins, bcr-abl/antagonists & inhibitors/genetics[MESH]|Gastrointestinal Stromal Tumors/*drug therapy/genetics/pathology[MESH]|Humans[MESH]|Imatinib Mesylate[MESH]|Mutation[MESH]|Piperazines/administration & dosage/pharmacology[MESH]|Protein-Tyrosine Kinases/antagonists & inhibitors[MESH]|Proto-Oncogene Proteins c-kit/genetics/metabolism[MESH]|Pyrimidines/administration & dosage/pharmacology[MESH]|Receptor, Macrophage Colony-Stimulating Factor/antagonists & inhibitors[MESH]|Receptors, Platelet-Derived Growth Factor/antagonists & inhibitors/genetics[MESH]|Skin Neoplasms/*drug therapy/pathology[MESH]|Treatment Outcome[MESH] |
